Lineage Cell Therapeutics LCTX
NYSE LCTX
$1.00 +0.02 (+2.03%)
As of: Oct 23, 2026 · 3:59 PM EDT

Lineage Cell Therapeutics (LCTX) Price to FCF (2022)

Updated

Lineage Cell Therapeutics' (LCTX) Price to FCF was 308.06 for Q4 2022, up 367.6% from the prior quarter.

Analysis

Lineage Cell Therapeutics (LCTX) Price to FCF (2022) Analysis & Trends

Dating back to Q1 2022, Lineage Cell Therapeutics' Price to FCF record includes 4 quarters.

  • Per Business Quant data, the three quarters before Q4 2022 came in at 65.88 (Q3 2022), 70.99 (Q2 2022) and 48.48 (Q1 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Lineage Cell Therapeutics 251.99 Mn 51.52 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 308.06
Sep 30, 2022 65.88
Jun 30, 2022 70.99
Mar 31, 2022 48.48
API Access

Lineage Cell Therapeutics Price to FCF API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-fcf&ticker=LCTX&period=max&api_key=YOUR_API_KEY